Sanofi India (BOM:500674) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,369.25
GF Value ₹4,402.68
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sanofi India's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BOM:500674 vs LLY, JNJ, ABBV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, Sanofi India's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi India Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Sanofi India's Margin of Safety % (DCF Earnings Based) falls into.


BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,369.25
Price
₹4,402.68
GF Value